English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Infections caused by extended-spectrum beta-lactamase (ESBL) producing E. coli and K. pneumoniae limit therapeutical options.The objective of this study was to evaluate the activity of ciprofloxacin, imipenem, amikacin and piperacillin/tazobactam against ESBL-producing E. coli and K. pneumoniae strains isolated from patients admitted to Ospedali Riuniti, Foggia, over the period January-December 2007. A total of 1013 E. coli and 146 K. pneumoniae were isolated from various clinical specimens. 111/1013 (10.9%) and 24/146 (16.4%) were confirmed as ESBL-producing strains by both the Phoenix system (Becton & Dickinson) and the E-test (bioMérieux, Italia). Both the ESBL producing enterobacteria showed a high degree resistance to ciprofloxacin; in addition, K. pneumoniae exhibited resistance also to piperacillin/tazobactam. Imipenem was the most effective antibiotic with the exception of one strain ESBL-positive K. pneumoniae. A similar pattern was showed by amikacin. In view of the increasing prevalence of ESBL strains it appears important a continuous antimicrobial monitoring

ESBL-producing E. coli and K. pneumoniae: prevalence and antimicrobial susceptibility